Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

Poster presentation at ASCO Annual Meeting 2026 in Chicago

We are pleased to share that Prof. Michael Weichenthal presented a EUMelaReg poster at this year's American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The poster explored the outcomes of adjuvant BRAF and MEK inhibition with dabrafenib and trametinib in patients with BRAF V600K-mutated melanoma compared to those with BRAF V600E mutations.

This work contributes valuable real-world evidence on treatment outcomes across different BRAF mutation subtypes and highlights the importance of further improving our understanding of melanoma heterogeneity to support individualized treatment strategies.

Congratulations to Michael Weichenthal and all collaborators involved in this important research.